Boston Scientific Corp (BSX) reported better-than-expected financial results for the third quarter of fiscal 2025. The company posted earnings per share (EPS) of $0.75, surpassing Wall Street's consensus estimate of $0.72 by $0.03. Revenue reached $5.1 billion, exceeding the anticipated $5.0 billion.
The announcement highlights Boston Scientific's robust operational performance. The firm is headquartered in Marlborough, Massachusetts, and employs approximately 53,000 full-time staff. It specializes in the development, manufacture, and marketing of medical devices used in interventional medical procedures across various segments, including MedSurg, Cardiovascular, and Neuromodulation.
Boston Scientific will host an earnings conference call at BMO to discuss these results and provide further insights into its business performance. Investors are encouraged to review the full earnings release and management commentary for a comprehensive understanding of the quarter's results and future outlook.
Looking ahead, the company is set to report its next earnings on April 20, 2026, with an EPS estimate of $0.7922 and revenue expected to be $5.3 billion.